The emerging role of non-coding circulating RNA as a biomarker in renal cell carcinoma

References

• Znaor A, Lortet-Tieulent J, Laversanne M, et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519–530.
   PubMed Web of Science ®Google Scholar
• Daugherty M, Blakely S, Shapiro O, et al. Chromophobe renal cell carcinoma is the most common nonclear renal cell carcinoma in young women: results from the SEER database. J Urol. 2016;95(4P1):847–851.
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–924.
   PubMed Web of Science ®Google Scholar
• Dietrich D, Meller S, Uhl B, et al. Nucleic acid-based tissue biomarkers of urologic malignancies. Crit Rev Clin Lab Sci. 2014;51(4):173–199.
   PubMed Web of Science ®Google Scholar
• Ralla B, Stephan C, Meller S, et al. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies. Crit Rev Clin Lab Sci. 2014;51(4):200–231.
   PubMed Web of Science ®Google Scholar
• Kamm RC, Smith AG. Nucleic acid concentrations in normal human plasma. Clin Chem. 1972;18(6):519–522.
   PubMed Web of Science ®Google Scholar
• Feng G, Li G, Gentil-Perret A, et al. Elevated serum-circulating RNA in patients with conventional renal cell cancer. Anticancer Res. 2008;28(1A):321–326.
   PubMed Web of Science ®Google Scholar
• Farazi TA, Hoell JI, Morozov P, et al. MicroRNAs in human cancer. Adv Exp Med Biol. 2013;774:1–20.
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838.
   PubMed Web of Science ®Google Scholar
• Gu L, Li H, Chen L, et al. MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis. Oncotarget. 2015;6(32):32545–32560.
   PubMed Web of Science ®Google Scholar
• Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141(5):672–675.
   PubMed Web of Science ®Google Scholar
• Kriebel S, Schmidt D, Holdenrieder S, et al. Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer. Plos One. 2015;10(1):e0117284.
   PubMed Web of Science ®Google Scholar
• Syring I, Bartels J, Holdenrieder S, et al. Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer. J Urol. 2015;193(1):331–337.
   PubMed Web of Science ®Google Scholar
• Scheffer AR, Holdenrieder S, Kristiansen G, et al. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol. 2014;32(2):353–358.
   PubMed Web of Science ®Google Scholar
• Mahn R, Heukamp LC, Rogenhofer S, et al. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology. 2011;77(5):1265.e9-1265.e16.
   PubMed Web of Science ®Google Scholar
• Wulfken LM, Moritz R, Ohlmann C, et al. MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. Plos One. 2011;6(9):e25787.
   PubMed Web of Science ®Google Scholar
• Iwamoto H, Kanda Y, Sejima T, et al. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int J Oncol. 2014;44(1):53–58.
   PubMed Web of Science ®Google Scholar
• Fedorko M, Stanik M, Iliev R, et al. Combination of MiR-378 and MiR-210 serum levels enables sensitive detection of renal cell carcinoma. Int J Mol Sci. 2015;16(10):23382–23389.
   PubMed Web of Science ®Google Scholar
• Zhao A, Li G, Peoc’h M, et al. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol. 2013;94(1):115–120.
   PubMed Web of Science ®Google Scholar
• Liu TY, Zhang H, Du SM, et al. Expression of microRNA-210 in tissue and serum of renal carcinoma patients and its effect on renal carcinoma cell proliferation, apoptosis, and invasion. Genet Mol Res. 2016;15(1):15017746. doi:10.4238/gmr.15017746
   Web of Science ®Google Scholar
• Redova M, Poprach A, Nekvindova J, et al. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med. 2012;10:55.
   PubMed Web of Science ®Google Scholar
• Wang C, Hu J, Lu M, et al. A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma. Sci Rep. 2015;5:7610.
   PubMed Web of Science ®Google Scholar
• Hauser S, Wulfken LM, Holdenrieder S, et al. Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol. 2012;36(4):391–394.
   PubMed Web of Science ®Google Scholar
• Teixeira AL, Ferreira M, Silva J, et al. Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumour Biol. 2014;35(5):4057–4066.
   PubMed Web of Science ®Google Scholar
• Sanders I, Holdenrieder S, Walgenbach-Brunagel G, et al. Evaluation of reference genes for the analysis of serum miRNA in patients with prostate cancer, bladder cancer and renal cell carcinoma. Int Journal Urology: Official Journal Jpn Urol Assoc. 2012;19(11):1017–1025.
   PubMed Web of Science ®Google Scholar
• Schulte C, Molz S, Appelbaum S, et al. miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease. Plos One. 2015;10(12):e0145930.
   PubMed Web of Science ®Google Scholar
• Zheng J, Zhou Z, Xu Z, et al. Serum microRNA-125a-5p, a useful biomarker in liver diseases, correlates with disease progression. Mol Med Rep. 2015;12(1):1584–1590.
   PubMed Web of Science ®Google Scholar
• Teng J, Sun F, Yu PF, et al. Differential microRNA expression in the serum of patients with nephrotic syndrome and clinical correlation analysis. Int J Clin Exp Pathol. 2015;8(6):7282–7286.
   PubMed Web of Science ®Google Scholar
• Hu YY, Dong WD, Xu YF, et al. Elevated levels of miR-155 in blood and urine from patients with nephrolithiasis. Biomed Res Int. 2014;295651:2014.
   Google Scholar
• Pritchard CC, Kroh E, Wood B, et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila). 2012;5(3):492–497.
   PubMed Web of Science ®Google Scholar
• Dang K, Myers KA. The role of hypoxia-induced miR-210 in cancer progression. Int J Mol Sci. 2015;16(3):6353–6372.
   PubMed Web of Science ®Google Scholar
• Ellinger J, Muller SC, Dietrich D. Epigenetic biomarkers in the blood of patients with urological malignancies. Expert Rev Mol Diagn. 2015;15(4):505–516.
   PubMed Web of Science ®Google Scholar
• Lu J, Xie F, Geng L, et al. Potential role of MicroRNA-210 as biomarker in human cancers detection: a meta-analysis. Biomed Res Int. 2015;303987:2015.
   Google Scholar
• Yu F, Yang J, Ouyang J, et al. Serum microRNA-210 levels in different groups of chronic hepatitis B patients. Clin Chim Acta. 2015;450:203–209.
   PubMed Web of Science ®Google Scholar
• Signorelli SS, Li Volsi G, Pitruzzella A, et al. Circulating miR-130a, miR-27b, and miR-210 in patients with peripheral artery disease and their potential relationship with oxidative stress: a pilot study. Angiology. 2016. doi:10.1177/0003319716638242
   Google Scholar
• Clark MB, Johnston RL, Inostroza-Ponta M, et al. Genome-wide analysis of long noncoding RNA stability. Genome Res. 2012;22(5):885–898.
   PubMed Web of Science ®Google Scholar
• Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinformatics. 2016;14(1):42–54.
   PubMed Web of Science ®Google Scholar
• Gibb EA, Vucic EA, Enfield KS, et al. Human cancer long non-coding RNA transcriptomes. Plos One. 2011;6(10):e25915.
   PubMed Web of Science ®Google Scholar
• Blondeau JJ, Deng M, Syring I, et al. Identification of novel long non-coding RNAs in clear cell renal cell carcinoma. Clin Epigenetics. 2015;7(1):10.
   PubMed Web of Science ®Google Scholar
• Deng M, Blondeau JJ, Schmidt D, et al. Identification of novel differentially expressed lncRNA and mRNA transcripts in clear cell renal cell carcinoma by expression profiling. Genomics Data. 2015;5:173–175.
   PubMed Web of Science ®Google Scholar
• Malouf GG, Zhang J, Yuan Y, et al. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol. 2015;9(1):32–43.
   PubMed Web of Science ®Google Scholar
• Qin C, Han Z, Qian J, et al. Expression pattern of long non-coding RNAs in renal cell carcinoma revealed by microarray. Plos One. 2014;9(6):e99372.
   PubMed Web of Science ®Google Scholar
• Ellinger J, Alam J, Rothenburg J, et al. The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. Am J Cancer Res. 2015;5(9):2799–2807.
   PubMed Web of Science ®Google Scholar
• Xue S, Li QW, Che JP, et al. Decreased expression of long non-coding RNA NBAT-1 is associated with poor prognosis in patients with clear cell renal cell carcinoma. Int J Clin Exp Pathol. 2015;8(4):3765–3774.
   PubMed Web of Science ®Google Scholar
• Kohls K, Schmidt D, Holdenrieder S, et al. [Detection of cell-free lncRNA in serum of cancer patients]. Urologe A. 2015;54(6):819–825.
   PubMedGoogle Scholar
• Kogure T, Yan IK, Lin WL, et al. Extracellular vesicle-mediated transfer of a novel long noncoding RNA TUC339: a mechanism of intercellular signaling in human hepatocellular cancer. Genes Cancer. 2013;4(7–8):261–272.
   PubMedGoogle Scholar
• Ren S, Wang F, Shen J, et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer. 2013;49(13):2949–2959.
   PubMed Web of Science ®Google Scholar
• Peng H, Wang J, Li J, et al. A circulating non-coding RNA panel as an early detection predictor of non-small cell lung cancer. Life Sci. 2016;151:235–242.
   Web of Science ®Google Scholar
• Wu Y, Wang YQ, Weng WW, et al. A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls. Oncogenesis. 2016;5:e192.
   PubMed Web of Science ®Google Scholar
• Wang K, Yuan Y, Cho JH, et al. Comparing the microRNA spectrum between serum and plasma. PLoS One. 2012;7(7):e41561.
   PubMed Web of Science ®Google Scholar
• Gallo A, Tandon M, Alevizos I, et al. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. Plos One. 2012;7(3):e30679.
   PubMed Web of Science ®Google Scholar
• Turchinovich A, Weiz L, Langheinz A, et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16):7223–7233.
   PubMed Web of Science ®Google Scholar
• Vickers KC, Palmisano BT, Shoucri BM, et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13(4):423–433.
   PubMed Web of Science ®Google Scholar
• Wang K, Li H, Yuan Y, et al. The complex exogenous RNA spectra in human plasma: an interface with human gut biota? Plos One. 2012;7(12):e51009.
   PubMed Web of Science ®Google Scholar
• Alvarez ML, Khosroheidari M, Kanchi Ravi R, et al. Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int. 2012;82(9):1024–1032.
   PubMed Web of Science ®Google Scholar
• Debey-Pascher S, Chen J, Voss T, et al. Blood-based miRNA preparation for noninvasive biomarker development. Methods Mol Biol. 2012;822:307–338.
   PubMedGoogle Scholar
• Zhu W, Zhou K, Zha Y, et al. Diagnostic value of serum miR-182, miR-183, miR-210, and miR-126 levels in patients with early-stage non-small cell lung cancer. Plos One. 2016;11(4):e0153046.
   PubMed Web of Science ®Google Scholar
• Thakur S, Grover RK, Gupta S, et al. Identification of specific miRNA Signature in paired sera and tissue samples of indian women with triple negative breast cancer. Plos One. 2016;11(7):e0158946.
   PubMed Web of Science ®Google Scholar
• Wang W, Qu A, Liu W, et al. Circulating miR-210 as a diagnostic and prognostic biomarker for colorectal cancer. Eur J Cancer Care (Engl). 2016. doi:10.1111/ecc.12448
   Google Scholar
• Cheng HH, Mitchell PS, Kroh EM, et al. Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. Plos One. 2013;8(7):e69239.
   PubMed Web of Science ®Google Scholar
• Kang SK, Huang WC, Pandharipande PV, et al. Solid renal masses: what the numbers tell us. AJR Am J Roentgenol. 2014;202(6):1196–1206.
   PubMed Web of Science ®Google Scholar